A Phase 1 interventional study of Cannabidiol (CBD) Powder and Cannabidiol 100 MG/ML [Epidiolex] in CBD Pharmacokinetics and Healthy Participants, sponsored by DSM Nutritional Products, Inc.. Completed at 1 site in Canada. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-17.
Sponsored by DSM Nutritional Products, Inc. (part of dsm-firmenich) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Cannabidiol (CBD), derived from the Cannabis sativa plant, is being investigated for its potential health benefit without the psychoactive properties and adverse reactions that arise from the use of delta-9-tetrahydrocannabinol (Δ9-THC). Few studies have characterized the pharmacokinetic (PK) effects and safety of oral CBD administration. Epidiolex (Epidyolex), an oil form of CBD, is the only marketed monotherapy approved by the United States Food and Drug Administration (FDA) and Health Canada. Delivery of a CBD in a powder/capsule form may provide a more efficient method for consumers.
The goal of this study is to characterize the PK profile of the test product, CBD-NE (a capsule formulation) compared to Epidyolex under both fasted and fed conditions. Each participant will receive a dose of each product under both fed and fasted conditions in a crossover design.
CBD and Δ9-THC are the most abundant extracts from the Cannabis sativa plant. Δ9-THC is typically associated with psychotropic effects due to its affinity for cannabinoid receptor types 1 and 2. CBD possesses a low affinity and lack of function at these receptors; therefore there is an interest in its potential health benefit without the psychoactive properties and adverse reactions that arise from Δ9-THC use. Only few studies have characterized the PK effects and the safety of oral CBD administration. As CBD is a lipophilic molecule, consuming CBD with a lipid formulation may increase its exposure. Additionally, CBD is known to have poor bioavailability when taken orally because it is rapidly metabolized by the liver to 7-hydroxycannabidiol (7-OH-CBD) and then to cannbidiol-7-oic acid (7-COOH-CBD), which may reduce the potency of CBD. Formulation strategies for orally consumed CBD products are being investigated to by-pass one or both of these limitations and improve the bioavailability of CBD. Epidyolex, a purified form of CBD, is delivered in a solution of sesame oil which aids absorption. Epidyolex, marketed and sold in the US and Canada as Epidiolex, is currently the only marketed CBD monotherapy with US FDA and Health Canada approval and is approved for treatment of certain types of epilepsy. However, administration of CBD in oil form is not ideal for consumers as it is not always convenient or precise. Delivery of CBD in a powder/capsule form may provide a more efficient method of CBD consumption.
The test product will be CBD-NE, a novel formulation of CBD in a powder form. This product will be investigated in healthy adults as its PK profile is not yet characterized in humans. This study is designed to be a randomized, crossover, comparator control trial to evaluate the PK profile and safety of CBD-NE compared to Epidyolex in healthy adults under both fed and fasted conditions.
Two study products, CBD-NE and Epidyolex, will be administered under both fed and fasted conditions. Participants will be randomized in a 1:1:1:1 ratio to one of 4 treatment sequences. There will be a total of 4 treatment periods consisting of 2 consecutive days, and one washout period. Each dose will be followed by a minimum 14-day, maximum of 28-day washout period, with the last dose followed by a follow-up phone call which will occur within the timeframe of the longest washout period over the study. For the fed state, participants will consume a high-fat, high-calorie breakfast within the 30 minutes prior to dosing.
Pharmacokinetic blood sampling will occur pre-dose and at 0.25 h, 0.5 h, 0.75 h, 1.0 h, 1.5 h, 2.0 h, 3.0 h, 4.0 h, 5.0 h, 6.0 h, 8.0 h, 12.0 h and 24.0 h post-dose.
Blood samples collected will be used to assess the PK profiles of CBD-NE and Epidyolex. PK parameters measured will include maximum concentration in plasma (Cmax), time to reach maximum concentration (Tmax), elimination half-life (T1/2), area under the plasma concentration-time curve over 24 hours (AUC0-24), area under the plasma concentration-time curve from zero to infinity (AUCinf) and AUC0-24/AUCinf for CBD, 7-OH-CBD and 7-COOH-CBD. Safety endpoints will be assessed throughout the study and will include reports of adverse events, 12-lead ECG, vital signs, safety laboratory assessments, and abbreviated physical exam.
DSM Nutritional Products, Inc. is the lead sponsor of 35 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
First submitted after DSM Nutritional Products, Inc. became part of dsm-firmenich.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of CBD-NE (6 capsules) following consumption of a high-fat, high-calorie breakfast
Drug: Cannabidiol (CBD) Powder
A single dose of CBD-NE (6 capsules) after a minimum 10-hour fast
Drug: Cannabidiol (CBD) Powder
A single dose of Epidyolex (4 mL oil) following consumption of a high-fat, high-calorie breakfast
Drug: Cannabidiol 100 MG/ML [Epidiolex]
A single dose of Epidyolex (4 mL oil) after a minimum 10-hour fast
Drug: Cannabidiol 100 MG/ML [Epidiolex]
66.68 mg CBD per capsule for a total of 400 mg CBD per serving
Also known as: CBD-NE
Drug page: Cannabidiol
100 mg CBD/mL for a total of 400 mg CBD per serving
Also known as: Epidyolex
Pharmacokinetic (PK) Properties of CBD-NE compared to Epidyolex under Fed Conditions
Area under the plasma concentration-time curve over 24 hours (AUC0-24) for CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fasted Conditions
AUC0-24 for CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidiolex under Fed Conditions
AUC0-24 for 7-hydroxycannabidiol (7-OH-CBD) and cannabidiol-7-oic acid (7-COOH-CBD)
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fasted Conditions
AUC0-24 for 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fed Conditions
Maximum concentration in plasma (Cmax) for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fasted Conditions
Cmax for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fed Conditions
Time to reach Cmax (Tmax) for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fasted Conditions
Tmax for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fed Conditions
Elimination half-life (T1/2) for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fasted Conditions
T1/2 for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fed Conditions
Area under the plasma concentration-time curve from zero to infinity (AUCinf) for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fasted Conditions
AUCinf for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fed Conditions
Ratio of AUC0-24 to AUCinf for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
PK Properties of CBD-NE compared to Epidyolex under Fasted Conditions
Ratio of AUC0-24 to AUCinf for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Total Drug Exposure of CBD-NE compared to Epidyolex under Fed Conditions
Sum of AUC0-24 of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Total Drug Exposure of CBD-NE compared to Epidyolex under Fasted Conditions
Sum of AUC0-24 of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Total Drug Exposure of CBD-NE compared to Epidyolex under Fed Conditions
Sum of AUCinf of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Total Drug Exposure of CBD-NE compared to Epidyolex under Fasted Conditions
Sum of AUCinf of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of CBD-NE under Fed and Fasted Conditions
AUC0-24 for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of Epidyolex under Fed and Fasted Conditions
AUC0-24 for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of CBD-NE under Fed and Fasted Conditions
Cmax for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of Epidyolex under Fed and Fasted Conditions
Cmax for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of CBD-NE under Fed and Fasted Conditions
Tmax for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of Epidyolex under Fed and Fasted Conditions
Tmax for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of CBD-NE under Fed and Fasted Conditions
T1/2 for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of Epidyolex under Fed and Fasted Conditions
T1/2 for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of CBD-NE under Fed and Fasted Conditions
AUCinf of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of Epidyolex under Fed and Fasted Conditions
AUCinf for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of CBD-NE under Fed and Fasted Conditions
Ratio of AUC0-24 to AUCinf for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of PK Properties of Epidyolex under Fed and Fasted Conditions
Ratio of AUC0-24 to AUCinf for CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of Total Drug Exposure of CBD-NE under Fed and Fasted Conditions
Sum of AUC0-24 of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of Total Drug Exposure of Epidyolex under Fed and Fasted Conditions
Sum of AUC0-24 of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of Total Drug Exposure of CBD-NE under Fed and Fasted Conditions
Sum of AUCinf of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Comparison of Total Drug Exposure of Epidyolex under Fed and Fasted Conditions
Sum of AUCinf of CBD, 7-OH-CBD and 7-COOH-CBD
Time frame: 0-24 hours
Assessment of 12-lead electrocardiogram (ECG)
Change from pre-dose to 12 h in QRS interval as assessed by 12-lead ECG
Time frame: 12 hours
Assessment of 12-lead electrocardiogram (ECG)
Change from pre-dose to 12 h in heart rate as assessed by 12-lead ECG
Time frame: 12 hours
Assessment of 12-lead electrocardiogram (ECG)
Change from pre-dose to 12 h in PR interval as assessed by 12-lead ECG
Time frame: 12 hours
Assessment of 12-lead electrocardiogram (ECG)
Change from pre-dose to 12 h in QT interval as assessed by 12-lead ECG
Time frame: 12 hours
Heart rate
Change from pre-dose to post-dose in heart rate (beats per minute)
Time frame: 0-24 hours
Blood pressure
Change from pre-dose to post-dose in systolic and diastolic blood pressure (mm Hg)
Time frame: 0-24 hours
Respiratory rate
Change from pre-dose to 24 h in respiratory rate (breaths per minute)
Time frame: 0-24 hours
Body Temperature
Change from pre-dose to 24 h in body temperature (°C)
Time frame: 0-24 hours
Composite Measure of Physical Abnormalities Observed in A Comprehensive Physical Exam
Presence or absence of physical abnormalities in general appearance
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of ears
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of eyes
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of nose
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of throat
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of skin
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of chest
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of lungs
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of abdomen
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of physical abnormalities of lymph nodes
Time frame: 12 hours
Composite Measure of Physical Abnormalities Observed in a Comprehensive Physical Exam
Presence or absence of neurological abnormalities
Time frame: 12 hours
Incidence of Adverse Events
Number of participants with adverse events
Time frame: minimum of 14 days, maximum of 28 days
Whole Blood Hemoglobin
Change from pre-dose in whole blood hemoglobin (g/dL)
Time frame: 12 hours
Whole Blood Hematocrit
Change from pre-dose in whole blood hematocrit (%)
Time frame: 12 hours
Whole Blood White Blood Cells
Change from pre-dose in whole blood white blood cells (x10\^3/uL)
Time frame: 12 hours
Whole Blood Neutrophils
Change from pre-dose in whole blood neutrophils (cells/uL)
Time frame: 12 hours
Whole Blood Eosinophils
Change from pre-dose in whole blood eosinophils (cells/uL)
Time frame: 12 hours
Whole Blood Basophils
Change from pre-dose in whole blood basophils (cells/uL)
Time frame: 12 hours
Whole Blood Lymphocytes
Change from pre-dose in whole blood lymphocytes (cells/uL)
Time frame: 12 hours
Whole Blood Monocytes
Change from pre-dose in whole blood monocytes (cells/uL)
Time frame: 12 hours
Whole Blood Mean Platelet Volume
Change from pre-dose in whole blood mean platelet volume (fL)
Time frame: 12 hours
Whole Blood Platelet Count
Change from pre-dose in whole blood platelet count (x10\^9/L)
Time frame: 12 hours
Whole Blood Red Blood Cell Count
Change from pre-dose in whole blood red blood cell count (x10\^6/uL)
Time frame: 12 hours
Whole Blood Red Blood Cell Distribution Width
Change from pre-dose in whole blood red blood cell distribution width (%)
Time frame: 12 hours
Whole Blood Mean Corpuscular Volume
Change from pre-dose in whole blood mean corpuscular volume (fL)
Time frame: 12 hours
Whole Blood Mean Corpuscular Hemoglobin
Change from pre-dose in whole blood mean corpuscular hemoglobin (pg)
Time frame: 12 hours
Whole Blood Mean Corpuscular Hemoglobin Concentration
Change from pre-dose in whole blood mean corpuscular hemoglobin concentration (g/dL)
Time frame: 12 hours
Serum Sodium
Change from pre-dose in serum sodium (mmol/L)
Time frame: 12 hours
Serum Potassium
Change from pre-dose in serum potassium (mmol/L)
Time frame: 12 hours
Serum Chloride
Change from pre-dose in serum chloride (mmol/L)
Time frame: 12 hours
Serum Urea
Change from pre-dose in serum urea (mg/dL)
Time frame: 12 hours
Serum Creatinine
Change from pre-dose in serum creatinine (umol/L)
Time frame: 12 hours
Serum Estimated Glomerular Filtration
Change from pre-dose in serum estimated glomerular filtration rate (mL/min/1.73\^2)
Time frame: 12 hours
Serum Total Protein
Change from pre-dose in serum total protein (g/dL)
Time frame: 12 hours
Serum Albumin
Change from pre-dose in serum albumin (g/dL)
Time frame: 12 hours
Serum Globulin
Change from pre-dose in serum globulin (g/dL)
Time frame: 12 hours
Serum Total Bilirubin
Change from pre-dose in serum total bilirubin (mg/dL)
Time frame: 12 hours
Serum Glucose
Change from pre-dose in serum glucose concentration (mg/dL)
Time frame: 12 hours
Serum Alanine Transaminase
Change from pre-dose in serum alanine transaminase concentration (U/L)
Time frame: 12 hours
Serum Aspartate Transaminase
Change from pre-dose in serum aspartate transaminase concentration (U/L)
Time frame: 12 hours
Serum Alkaline Phosphatase
Change from pre-dose in serum alkaline phosphatase concentration (U/L)
Time frame: 12 hours
Gamma Glutamyl Transferase
Change from pre-dose in serum gamma glutamyl transferase concentration (U/L)
Time frame: 12 hours
Ran from Aug 2024 to primary completion in Nov 2024, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
DSM Nutritional Products, Inc. →